GlassScriptPhysician profile
Bryan Sauter
NPI 1407944820
$10,887.12
in general payments reported to CMS, 2019-2025
35 companies · $3,443 in 2025
The $3,443 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,925 · 2022: $1,932 · 2023: $1,331 · 2024: $2,258 · 2025: $3,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,356 · Consulting Fee: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,355.92 |
| Consulting Fee | $675.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,904.15 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $2,349.52 | 2021-2025 | |
| Janssen Biotech, INC. | $1,291.55 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $548.09 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $513.73 | 2022-2025 | |
| Madrigal Pharmaceuticals | $462.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $361.52 | 2021-2024 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $217.03 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $195.99 | 2023-2025 | Voquezna |
| Axonics, INC. | $192.78 | 2021-2024 | Axonics |
| Ardelyx, INC. | $169.44 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $159.56 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $146.84 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $126.33 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $126.22 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $125.69 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $124.89 | 2023 | Dupixent |
| Boston Scientific Corporation | $114.47 | 2025 | Axonics |
| Aimmune Therapeutics, INC. | $91.33 | 2025 | Vowst |
| Pfizer INC. | $86.24 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $85.17 | 2022-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $77.88 | 2021-2024 | Dificid |
| Braintree Laboratories, INC. | $60.41 | 2021-2022 | |
| Celgene Corporation | $59.02 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $45.93 | 2023-2025 | Rebyota |
| Myriad Women'S Health, INC. | $42.99 | 2023 | Myrisk |
| Vivus LLC | $38.85 | 2025 | Qsymia |
| Celltrion USA INC. | $34.63 | 2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.39 | 2023 | |
| Dexcom, INC. | $24.67 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $19.11 | 2025 | Wegovy |
| Mannkind Corporation | $17.71 | 2025 | |
| Corcept Therapeutics | $17.00 | 2025 | Korlym |
| Recordati_rare_diseases_inc. | $16.22 | 2025 | Isturisa |
| Acella Pharmaceuticals, LLC | $13.74 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Sauter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.